Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study
January 13, 2016 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density...